Prime Medicine launches with gene editing technology

By The Science Advisory Board staff writers

July 13, 2021 -- Prime Medicine has launched with $315 million in financing to rapidly advance its prime editing gene editing technology.

Prime editing acts like a DNA word processor to "search and replace" disease-causing genetic sequences at their precise location in the genome, without resulting in double-stranded DNA breaks that cause unwanted cellular changes.

The company is currently using prime editing to advance multiple drug discovery programs targeted at liver, eye, ex vivo hematopoietic stem cell, and neuromuscular indications.

Prime Medicine has secured $115 million in series A funding in addition to support with $200 million in series B financing approximately nine months after the company began operations.

Furthermore, Prime Medicine and Beam Therapeutics have built a partnership to form a collaborative approach to fighting diseases and accelerate the development of Prime editing to deliver therapies for patients. In the areas of partnership, Prime Medicine and Beam share research, expertise, and intellectual property for assays, know-how, delivery, and manufacturing.

The Broad Institute of MIT and Harvard (where the technology was developed) has extended a license for prime editing technology to Prime Medicine for human therapeutic uses under the Broad Institute's inclusive innovation model.

By the end of 2021, Prime Medicine plans to employ more than 100 full-time employees.

Apellis, Beam to apply base editing for disease discovery
Apellis Pharmaceuticals and Beam Therapeutics announced an exclusive five-year research collaboration focused on Beam's proprietary base editing technology...

Copyright © 2021 scienceboard.net


Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter